H. Lundbeck Management

Management criteria checks 1/4

H. Lundbeck's CEO is Deborah Dunsire, appointed in Sep 2018, has a tenure of 3.83 years. total yearly compensation is DKK56.60M, comprised of 17.5% salary and 82.5% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth €37.19K. The average tenure of the management team and the board of directors is 3.4 years and 1.3 years respectively.

Key information

Deborah Dunsire

Chief executive officer

kr.56.6m

Total compensation

CEO salary percentage	17.5%
CEO tenure	3.8yrs
CEO ownership	0.0008%
Management average tenure	3.4yrs
Board average tenure	1.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Deborah Dunsire's remuneration changed compared to H. Lundbeck's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2022	n/a	n/a	kr.1b
Dec 31 2021	kr.57m	kr.10m	kr.1b
Sep 30 2021	n/a	n/a	kr.2b
Jun 30 2021	n/a	n/a	kr.2b
Mar 31 2021	n/a	n/a	kr.2b
Dec 31 2020	kr.26m	kr.10m	kr.2b
Sep 30 2020	n/a	n/a	kr.904m
Jun 30 2020	n/a	n/a	kr.1b
Mar 31 2020	n/a	n/a	kr.2b
Dec 31 2019	kr.21m	kr.9m	kr.2b
Sep 30 2019	n/a	n/a	kr.3b
Jun 30 2019	n/a	n/a	kr.3b
Mar 31 2019	n/a	n/a	kr.4b
Dec 31 2018	kr.14m	kr.3m	kr.4b

Compensation vs Market: Deborah's total compensation ($USD7.76M) is above average for companies of similar size in the Austrian market ($USD2.46M).

Compensation vs Earnings: Deborah's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Deborah Dunsire (60 yo)

3.8yrs

Tenure

kr.56,600,000

Compensation

Dr. Deborah Dunsire, M.D. serves as Director at Syros Pharmaceuticals, Inc. since September 09, 2021. She serves as Chief Executive Officer and President at H. Lundbeck A/S since September 1, 2018 and serv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Deborah Dunsire	President & CEO	3.8yrs	kr.56.60m	0.00078% DKK 37.2k
Jacob Tolstrup	Executive VP of Commercial Operations & Chief Commercial Officer	4.7yrs	kr.8.70m	0.000030% DKK 1.4k
Lars Bang	Executive Vice President of Product Development & Supply	3.5yrs	kr.9.00m	0.0050% DKK 236.0k
Per Luthman	Executive Vice President of Research & Development	3.5yrs	kr.8.40m	0.00045% DKK 21.5k
Bjorn Mogensen	Senior Vice President Group Finance	no data	no data	no data
Tarek Samad	Senior VP & Head of Research	1.2yrs	no data	no data
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	no data	no data
Elise Hauge	Executive Vice President of People & Communication	2.8yrs	no data	0.00012% DKK 5.7k
Ole Chrintz	Senior Vice President of International Markets	no data	no data	no data
Keld Jorgensen	Executive Vice President of Corporate Strategy & Business Development	3.3yrs	no data	no data
Rupert Sandbrink	Senior VP & Head of Clinical Development	less than a year	no data	no data
Bjørn Grønning	Vice President of Clinical Research Neurology	no data	no data	no data

3.4yrs

Average Tenure

59yo

Average Age

Experienced Management: LUN's management team is considered experienced (3.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jeremy Levin	Independent Director	5.5yrs	no data	no data
Lars Rasmussen	Independent Chairman	9.5yrs	no data	0.0020% DKK 95.8k
Lene Skole-Sorensen	Deputy Chairman	7.5yrs	no data	0.0021% DKK 101.1k
Jeffrey Berkowitz	Independent Director	4.3yrs	no data	no data
Lars Holmqvist	Director	7.5yrs	no data	0.0015% DKK 72.0k
Dorothea Wenzel	Independent Director	1.3yrs	no data	no data
Santiago Arroyo	Independent Director	1.3yrs	no data	no data
Camilla Andersson	Employee Representative Director	less than a year	no data	no data
Dorte Clausen	Employee Representative Director	less than a year	no data	no data
Hossein Armandi	Employee Representative Director	less than a year	no data	no data
Lasse Skibsbye	Employee Representative Director	less than a year	no data	no data

1.3yrs

Average Tenure

60yo

Average Age

Experienced Board: LUN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

H. Lundbeck Management

Management criteria checks 1/4

Key information

Recent management updates

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Recent updates

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

H. Lundbeck A/S Common Stock to Be Deleted from OTC Equity

First quarter 2022 earnings released: EPS: kr.2.07 (vs kr.3.13 in 1Q 2021)

H. Lundbeck A/S Provides Earnings Guidance for the Year 2022

Less than half of directors are independent

H. Lundbeck A/S Completes Global Phase Iv, Randomized, Comparative Study Exploring the Role of Vortioxetine

H. Lundbeck A/S Appoints Joergornstein as Member of Lundbeck's Executive Management

Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI

Less than half of directors are independent

Upcoming dividend of kr.2.00 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

H. Lundbeck A/S Proposes Dividend for the Year 2021

EU Commission Approves Vyepti[®] (Eptinezumab) for the Preventive Treatment of Migraine in Adults

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17

Third quarter 2021 earnings released: EPS kr.1.62 (vs kr.2.38 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr.1.90 (vs kr.2.93 in 2Q 2020)

First quarter 2021 earnings released: EPS kr.3.13 (vs kr.0.76 in 1Q 2020)

H. Lundbeck A/S Provides Revenue Guidance for the Full Year of Fiscal 2021

H. Lundbeck A/S Announces New Study Finds That Vortioxetine Helps Patients with MDD and Comorbid Generalized Anxiety Disorder

Independent Director has left the company

H. Lundbeck A/S Appoints Tarek Samad as Head of Research, Effective on May 1, 2021

H. Lundbeck A/S Announces Resignation of Henrik Andersen from Board

Full year 2020 earnings released: EPS kr.7.95 (vs kr.13.42 in FY 2019)

New 90-day high: €33.92

Revenue misses expectations

New 90-day high: €28.98

Rigshospitalet and Lundbeck Announce Partnership to Find New Ways to Treat Brain Diseases

Lundbeck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Eptinezumab for the Prevention of Migraine

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2020

H. Lundbeck A/S Revises Earnings Guidance for the Year 2020

Revenue beats expectations

Third quarter 2020 earnings released: EPS kr.2.38

OVATION Pharmaceuticals, Inc. acquired Buronil from H. Lundbeck A/S.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age